Uzedy partners Teva and MedinCell's latest long-acting schizophrenia candidate notches phase 3 win
After bringing slow-release schizophrenia drug Uzedy to market last year, Teva and France’s MedinCell are using the same playbook for a similar candidate. With a phase 3 win, the duo is on their way to striking gold twice. Where Uzedy used MedinCell’s …